Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono presents positive trial data for MS drug

Merck Serono presents positive trial data for MS drug

19th April 2010

Merck Serono has published data from a phase III clinical trial underlining the efficacy of its multiple sclerosis (MS) drug cladribine.

According to the results of the Clarity trial, patients using Merck Serono’s drug saw a statistically significant increase in health benefits when compared to a placebo control group.

These included a decrease in the number of relapses, as well as a reduction in their dependence on societal support and healthcare resources.

Bernhard Kirschbaum, Merck Serono’s head of global research and development, said the analysis underlines the “relevance” of this latest trial of its investigational oral treatment.

He added: “We are committed to continuing to work with regulatory authorities to bring cladribine tablets to patients at the earliest point in time.”

This data was revealed by Merck Serono at the 62nd Annual Meeting of the American Academy of Neurology, where the company also presented new data on the long-term efficacy of its established MS treatment Rebif.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.